Typing

Via Death to Stock Photo

Ah grant writing. A mainstay of academic life, a necessary evil to keep treading the murky waters of scientific endeavour. So why not let us take you on a cheeky coffee break with some of the best bits from down the back of the internet sofa. Who knows, there might even be cake…

Are investors still squeamish about putting money into women’s health?

Given that women make up 50% of the population, you’d think that female-specific health products would be a clear commercial win. But according to this article from Fast Company, many investors still consider women’s products “too niche” for investment. 

Resilient British science will withstand Brexit

In the face of significant concerns about the post-Brexit future of British science, Ehsan Masood, editor of Research Fortnight, offers reasons to be cheerful. He argues that UK scientists have had to fight to stay international before, and they must not stop now.

They’re super healthy, but dying of heart disease. What’s happening to astronauts?

STAT take a look at the worrying news that deep space radiation could be linked to cardiac disease in astronauts. Several Apollo astronauts succumbed early in life to heart disease — and deep space radiation may be to blame, according to a study published Thursday in Nature’s Scientific Reports.

Alere faces criminal probe over Medicare, Medicaid billing

Step aside Theranos, the Wall Street Journal has another diagnostic company in its crosshairs. This week the Journal reported that Federal investigators are seeking information about government-billing practices at Alere Inc, which specialises in tests for HIV, tuberculosis and the presence of drugs and other toxins, adding to a litany of woes at the diagnostic-testing company as it seeks to complete a $5 billion deal to sell itself.

And one from us…

Americans appear wary of gene-editing, even to treat disease

Gene-editing has got more people worried than enthusiastic, according to new research. A Pew Research Center survey of US adults has revealed widespread wariness and worry about cutting-edge biotechnology.